S1192
Clinical - Urology
ESTRO 2026
PR25 questionnaires. The goal was to determine if the urinary and bowel symptoms on PR25 and the global QoL on C30 were non-inferior with SBRT in the first year after the start of RT, with the key time point being 3 months from the end of RT. The minimum clinically important (MCI) difference in scores was considered as 10 for the symptom scales and 6 for the Global QoL score for non-inferiority assessment. Linear mixed models were used as the primary method for comparison. Results: All QoL scores were well matched at baseline. The trajectory of scores is shown in Figure 1. The scores at 3 months for MHRT and SBRT for the urinary symptoms (17.2, 95% CI 15 -20 vs. 16.3, 95% CI 14- 18, p=0.7), bowel symptoms (5.6, 95% CI 4.2-7.1 vs. 5.1 95% CI 4.0-6.2, p=0.4) and global QoL (73.1, 95% CI 71- 76 vs. 72.3 95% CI 70-75, p=0.6) were all well within non-inferiority bounds and not significantly different. Also at 3 months, the proportion of patients in MHRT and SBRT arms with MCI worsening of urinary (24% vs 22%, p = 0.64) or bowel symptoms (9.5% vs 8.2%, p = 0.80) was similar. Modelling over one year demonstrated a significant effect of time, with initial worsening followed by improvement of scores. However, the pattern of change over time was not significantly different between SBRT and MHRT for all three parameters (p = 0.226, 0.319, 0.785 for urinary, bowel, and global scores). Prior TURP did not significantly modify the effect of the treatment arm on the symptom trajectory. Weekly or alternate-day treatment in the SBRT arm also did not modify the
Fig. 1 Biochemical relapse free survival in hypofractioated (red) and classical (blue) groups Conclusion: MFH EPLNI characterized by high efficacy with low risk of long-term serious complications. Keywords: hypofractionation, prostate cancer, radiotherapy
Proffered Paper 1722
Early quality-of-life outcomes in a randomised trial of prostate radiotherapy in high-risk and N+ with moderate or extreme hypofractionation (PRIME) Indranil Mallick 1 , Moses Arunsingh 1 , Priyamvada Maitre 2 , Saheli Saha 1 , Maneesh Singh 2 , Parth Verma 2 , Abhilash Gavarraju 2 , Tejshri Telkhade 2 , Ketaki Adsul 2 , Shashank Shenoy 1 , Ankita Mallick 1 , Sunanda Saha 1 , Pallavi Singh 2 , Sham C Sundar 3 , Srinivas Chilukuri 3 , Vedang Murthy 2 1 Department of Radiation Oncology, Tata Medical Center, Kolkata, India. 2 Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. 3 Department of Radiation Oncology, Apollo Proton Cancer Center, Chennai, India Purpose/Objective: The PRIME trial is a multi-institutional randomized trial assessing non-inferiority of extreme vs. moderately hypofractionated radiation therapy (SBRT/MHRT) in high-risk and node-positive prostate cancer. We report the quality-of-life outcomes of the first year. Material/Methods: A total of 526 patients meeting eligibility criteria were randomized 1:1 to MHRT (either 68Gy in 25 or 62 Gy in 20 fractions) or SBRT (36.25 Gy in 5 fractions, on alternate days or weekly) with elective pelvic radiotherapy and 24 months of androgen deprivation. A key secondary endpoint was the patient-reported quality of life (QoL) using the EORTC QLQ-C30 and
symptom trajectory.
Made with FlippingBook - Share PDF online